Potential Impact of Regorafenib in Patients With HCC

June 16, 2016
Ghassan K. Abou-Alfa, MD

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential impact that regorafenib (Stivarga) could have on the treatment landscape of hepatocellular carcinoma (HCC).